# Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects

> **NCT03296800** · PHASE1 · COMPLETED · sponsor: **Theracos** · enrollment: 48 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Bexagliflozin
- **DRUG:** Probenecid
- **DRUG:** Rifampin
- **DRUG:** Verapamil

## Key facts

- **NCT ID:** NCT03296800
- **Lead sponsor:** Theracos
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-27
- **Primary completion:** 2017-12-06
- **Final completion:** 2017-12-06
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2021-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03296800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03296800, "Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03296800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*